ctkb: the income statement

MyFinsight

Cytek Biosciences, Inc. (CTKB)

For the quarter ending 2025-06-30, CTKB made $45,602K in revenue. -$5,583K in net income. Net profit margin of -12.24%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30	2025-03-31	2024-09-30	2024-06-30
Total revenue, net	45,602	41,457	51,500	46,617
Service	6,814	-	-	-
Product	14,921	-	-	-
Total cost of sales	21,735	21,300	22,495	21,181
Gross profit	23,867	20,157	29,005	25,436
Sales and marketing	12,134	12,509	12,429	12,268
Research and development	8,826	9,725	9,882	10,001
General and administrative	13,531	12,898	10,942	11,694
Total operating expenses	34,491	35,132	33,253	33,963
Loss from operations	-10,624	-14,975	-4,248	-8,527
Other income, net	3,708	3,492	3,091	59
Interest income	555	508	1,433	1,416
Interest expense	414	291	119	134
Total other income, net	3,849	3,709	4,405	1,341
Loss before income taxes	-6,775	-11,266	157	-7,186
(benefit from) provision for income taxes	-1,192	136	-784	3,248
Net loss	-5,583	-	-	-
Net loss	-	-11,402	941	-10,434
Net loss, basic	-5,583	-11,402	941	-10,434
Net income (loss), diluted	-	-	941	-10,434

Weighted-average shares used in calculating net loss per share, basic (in shares)	126,934,294	128,339,481	131,003,744	131,440,486
Weighted-average shares used in calculating net loss per share, diluted (in shares)	126,934,294	128,339,481	132,785,552	131,440,486

Unit: Thousand (K) dollars (except for numbers of shares and EPS)